{"version":"1.0","provider_name":"Department of Medicine","provider_url":"https:\/\/www.med.unc.edu\/medicine","author_name":"Kim Morris","author_url":"https:\/\/www.med.unc.edu\/medicine\/news\/author\/kcmorris\/","title":"What's Best for Diabetes After Metformin? | Department of Medicine","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"TALxo9yfrJ\"><a href=\"https:\/\/www.med.unc.edu\/medicine\/news\/whats-best-for-diabetes-after-metformin\/\">What&#8217;s Best for Diabetes After Metformin?<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.med.unc.edu\/medicine\/news\/whats-best-for-diabetes-after-metformin\/embed\/#?secret=TALxo9yfrJ\" width=\"600\" height=\"338\" title=\"&#8220;What&#8217;s Best for Diabetes After Metformin?&#8221; &#8212; Department of Medicine\" data-secret=\"TALxo9yfrJ\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/10\/john-buse-podcast-e1612285894585.jpg","thumbnail_width":245,"thumbnail_height":252,"description":"Results of the five-year GRADE trial, designed to understand the best second-line agent for patients with type 2 diabetes already taking metformin, were reported at the virtual American Diabetes Association (ADA) 81st Scientific Sessions and published in\u00a0Medscape Medical News. Researchers found the injectable drugs Lantus (glargine) and Victoza (liraglutide) outperformed the pills Amaryl (glimepiride) and &hellip; Read more"}